The ICR Westwicke Blog is designed to deliver information and insights into the ever-changing world of healthcare communications.
For every healthcare company, public or private, the anticipation of clinical trial data represents an important, high-pressure milestone in its communications planning. For a public company, there is an obligation to disclose data within a reasonable timeframe. For a private company, while there isn’t an obligation to shareholders, there is pressure from private investors, the medical community, advocates, and even patients.
The Walt Disney Company and its CEO Bob Chapek are paying a high price for staying outside of politics, and then jumping into it. Disney’s entanglements with its employees on one side and Florida’s governor and lawmakers have spilled over with very real implications. Gov. Ron DeSantis has signed into law a bill that strips Disney of its special tax status in the state, a move which will effectively change how the company operates.
For CEOs and company leaders, interacting with the media isn’t an option — it’s a necessity. The media plays a significant role in telling your company story and shaping your public image. To ensure they tell an accurate story, however, it’s essential to learn how to work with the media and strive to understand how the industry is shifting.
Over the last 25 years, I have listened to hundreds of earnings calls. As a sell-side analyst, they were a routine and not-much-fun part of the job. Four times a year, you lock yourself in your office and listen to call after call of management teams highlighting their achievements or trying to sugar coat the not-so-positive news.
Most of the calls were pretty standard, and came off as well thought-out and comprehensive. But every so often you would hear that call where the sell-side analysts were unforgiving in their questions and the tone was so negative you almost feel bad for the management team. In my role here at ICR Westwicke, I’ve learned what really goes on behind the scenes to make those effective earnings calls appear effortless: a lot of hard work and practice starting about a month ahead of time. Who would have ever thought?
Creating an investor relations strategy is no small task — but it’s a critical step for any public company. To meet the expectations of investors and analysts, company leaders must develop a strategic approach for messaging, earnings calls, guidance, conferences, investor interactions and more. While that can seem overwhelming, an effective IR process actually boils down to just seven essential elements. With a plan for each of these areas, you can build a quality, long-term shareholder base and enhance equity market value.
Public healthcare companies often question the best course of action during quiet periods – those stretches of time during which they should limit their interaction with Wall Street due to their knowledge of material and timely information that has not yet been disclosed. Specifically, management teams struggle to figure out what the quiet period means for their investor relations (IR) efforts.
If your company is publicly traded or a private company preparing for an IPO, then you likely have two separate communication tasks, one focused on reaching investors and financial analysts, the other on reaching customers and the general public – investor relations and public relations.
The last year has been challenging for businesses — from global pandemic, economic uncertainty and supply chain disruptions to labor shortages and growing concern over inflation — but there was also robust activity in the financial markets, and in healthcare specifically. See what you missed in 2021 with our most-read posts of the year.
The COVID-19 pandemic continues to drive significant changes to nearly every industry, from real estate to staffing to consumer goods — but it fundamentally changed how consumers view and access healthcare. As the U.S. continues to navigate the pandemic, alongside mixed economic data, supply chain challenges, and labor challenges, what lies ahead for the healthcare industry in 2022? Below, our experts offer their predictions.
Investors know that biotech and biopharma companies in the early development stages can be risky investments. So finding the right investors that believe the rewards will outweigh the risks requires strategy.
